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Abstract: Developing nontraditional approaches to the synthesis and characterization of multivalent 
compounds is critical to our efforts to study and interface with biological systems and to build new 
noncovalent materials.  This paper demonstrates a biomimetic approach to the construction of discrete, 
modular, multivalent receptors via molecular self-assembly in aqueous solution.  Scaffolds presenting 
1–3 viologen groups recruit a respective 1-3 copies of the synthetic host, cucurbit[8]uril, in an 
noncooperative manner and with a consistent equilibrium association constant (Ka) value of 2 x 10
6 M-1 
per binding site.  The assembled mono-, di-, and trivalent receptors bind to their cognate target peptides 
containing 1-3 Trp residues with Ka values in the range 1.7 x 10
4 to 4.7 x 106 M-1 and in predetermined 
mono- or multivalent binding modes with 31-280-fold enhancements in affinity and additive enthalpies 
due to multivalency.  The extent of valency was determined directly by measuring the visible charge-
transfer absorptivity due to the viologen-indole pair.  The predictable behavior of this system and its 
ease of synthesis and analysis make it well suited to serve as a model for multivalent binding and for the 
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multivalent recognition of peptides by design. 
Introduction 
The simultaneous association of multiple ligands on one entity with multiple receptors on another—
“multivalent binding”—is believed to play a fundamental role in myriad biochemical processes, 
including signal transduction, pathogenic infection and the immune response, and is involved in the 
bottom-up molecular self-assembly of nanoscale architectures.1 Exploring new methods for the 
synthesis and characterization of multivalent compounds is therefore critical to our efforts to study and 
interface with biological systems and to build new materials.  In recent years, substantial interest in this 
field has produced a wide range of synthetic multivalent compounds1a, 2 as well as experimental 
methods and theoretical models to describe their behavior.3 Despite the successful development of many 
compounds that exhibit increased affinity and/or selectivity due to multivalency, however, little is 
known about how to control the cooperation of multiple binding events by design. 
 
Figure 1.  Structures of Q8, MV, and Trp, and a schematic of the Q8•MV•Trp complex. 
Progress in this area has been slowed by difficulties inherent to synthesizing multivalent receptors 
and to determining the number of simultaneous interactions per complex.  The principle approach to 
synthesizing multivalent compounds involves covalently connecting multiple copies of a ligand,2b or a 
synthetic host (e.g., cyclodextrin, vancomycin, or crown ether),4 either by direct linkage or by 
attachment to a common scaffold.  While this approach is typically straightforward for the linkage of 
small ligands, the linkage of large, polar, and structurally repetitive host compounds is exceedingly slow 
and costly, especially for iterative structure-activity studies.  Moreover, standard equilibrium binding 
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assays are based on comparing the relative quantities of bound and unbound states but do not readily 
reveal the extent of valency (i.e., the number of simultaneous associations) in the bound state.5 This 
paper describes a multivalent system, based on cucurbit[8]uril (Q8, Figure 1), that overcomes these 
issues of synthesis and analysis. 
Q8 is a member of the cucurbit[n]uril (Qn) family of synthetic macrocyclic hosts,6 which have 
gained enormous interest in recent years due to their ability to bind tightly and selectively to a wide 
range of cationic organic compounds in aqueous solution.7  The methylene-bridged glycoluril units of a 
Qn molecule surround its hydrophobic cavity and present ureido carbonyl oxygens at the two 
constricted entrances (or portals) to this cavity.  These structural features promote binding through a 
combination of hydrophobic inclusion of the guest and alignment of its cationic group(s) with the 
oxygen atoms of the Qn.  While Q5, Q6, and Q7 typically bind one equivalent of organic guest, multiple 
guests can be accommodated simultaneously by Q8,6b, 8 Q10,9 and nor-seco-Q10.10  Q8 binds to one 
equivalent of methyl viologen (MV) with an equilibrium association constant (Ka) value of 10
5-106 M–
1,8a, 11 and the resulting Q8•MV complex can then bind efficiently to electron-rich aromatic guests such 
as dopamine or tryptophan (Trp).12  We have previously reported the binding of Q8•MV to Trp-
containing peptides with Ka values in the range 10
3-105 M-1, depending on the peptide sequence.11  
Moreover, the binding of Trp to Q8•MV is accompanied by the quantitative formation of a new visible 
absorbance (hence, optical sensing) due to a charge-transfer complex between the indole and viologen 
groups.11, 12b  The interesting properties of the Q8•MV•Trp system led us to consider a biomimetic 
approach to making model multivalent receptors. 
Living systems use hierarchical organization to efficiently accomplish a broad diversity of function.  
At each level of hierarchy, the components carry out functions intrinsic to that level and also have the 
ability to work together to achieve higher-level functions.  For example, proteins such as cell-surface 
receptors or viral capsid proteins can bind their targets in a monovalent fashion and also have the ability 
to assemble noncovalently into multivalent structures with increased affinity and/or selectivity of 
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binding, or with new function such as pore formation or encapsulation.1a, d  Here we show how Q8 can 
mimic these proteins via its unique ability to bind selectively to two different guests: 1) a target peptide; 
and 2) a viologen that can be used to direct its noncovalent assembly with other Q8 molecules.  In the 
scheme shown in Figure 2, two molecules of Q8 assemble onto a scaffold presenting two viologen 
groups.  The resulting self-assembled receptor then binds in a discrete divalent fashion to a peptide with 
two tryptophan residues.   
 
Figure 2.  Schematic illustration of the concept of a self-assembling modular receptor.  A divalent scaffold presenting viologen groups (in red) 
recruits two equivalents of Q8, and the resulting receptor binds in a divalent fashion to a peptide with two tryptophan groups (in blue). 
Peptide-based scaffolds functionalized with one, two, or three (n) viologen groups were prepared by 
solid phase methods.  Isothermal titration calorimetry was used to determine the thermodynamic 
parameters for the binding of these compounds to n equivalents of Q8 (i.e., receptor assembly), and for 
the binding of the resulting self-assembled receptors to peptides containing n Trp residues, respectively.  
We find that all receptors assemble in a noncooperative manner and then bind to their cognate peptide 
targets in predetermined mono- or multivalent modes with 31- to 280-fold increases in affinity due to 
multivalency, all in aqueous solution at pH 7.  The built-in optical sensor, based on the Trp-MV charge-
transfer complex, allows for direct quantitation of the extent of valency in each complex using UV-
visible spectroscopy.  To the best of our knowledge, this is the first time it has been possible to direct 
the noncovalent assembly of multiple synthetic hosts into discrete multivalent constructs while still 
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maintaining the capacity for the hosts to bind to a target guest.  Moreover, the predictable behavior of 
this system and its ease of synthesis and analysis make it well suited to serve as a model for multivalent 
binding and for the multivalent recognition of peptides by designed molecules.13 
 
Results 
Synthesis.  Compounds 1-6 (Figure 3)14 were synthesized on solid-support by standard fmoc 
protocols, purified by reversed phase HPLC, and characterized by 1H NMR, analytical HPLC, and mass 
spectrometry.  For compounds 1-3 we developed a new synthetic strategy for linking viologen groups to 
a peptide on solid support.  Briefly, dimethylbenzyl-protected glutamic acid (Glu) residues were 
installed at positions where viologen groups were to be coupled.  After acetylation of the N-terminal 
amine, the Glu residues were deprotected in dilute acid, then activated with pentafluorophenol and 
diisopropylcarbodiimide and coupled in situ to an aminoethyl derivative of methyl viologen (see 
Supporting Information for details). 
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Figure 3.  Chemical structures of compounds 1-6. 
 
Equilibrium Binding Studies.  The binding of Q8 to compounds 1-3 was measured by ITC to 
determine the stoichiometry and affinity of complexation.15  The data in Table 1 show that scaffold 
compounds 1, 2, and 3 bind to one, two, and three molar equivalents of Q8 to form receptor complexes 
1•Q8, 2•Q82, and 3•Q83, respectively.  Ka values were virtually identical for all scaffolds tested.  The 
presence of all complexes was confirmed by electrospray mass spectrometry (ESI-MS). 
 
Table 1.  Binding of Scaffolds to Q8. 
Scaffold Ka (M
-1)a 
 7 
1a 
1b 
2a 
2b 
3 
2.1 (±0.1) x 106 
2.0 (±0.1) x 106 
2.2 (±0.3) x 106 
2.1 (±0.2) x 106 
 1.6 (±0.1) x 106 
aData were fit to a one set of sites model in Origin 7.0 software. Standard deviations are given in 
parentheses. Values were determined from at least three ITC experiments in 10 mM sodium phosphate, 
pH 7.0, at 27 C. 
 
Receptors were preassembled by mixing viologen-containing compounds, 1, 2, and 3, with one, two, 
and three molar equivalents of Q8, respectively.  Binding of the resulting receptor complexes, 1•Q8, 
2•Q82, and 3•Q83, to target peptides 4-6 was measured by ITC to determine the stoichiometry and 
thermodynamic parameters of complexation (Table 2).  The divalent and trivalent receptor complexes 
were kept in the sample cell of the calorimeter at concentrations at or above 20 µM to ensure that the 
majority of Q8 was bound to viologen during the experiment.  Monovalent, divalent, and trivalent 
receptors, 1•Q8, 2•Q82, and 3•Q83, bound to one, two, and three molar equivalents, respectively, of 
monovalent target peptides, 4 (i.e., 4a and 4b).  Each divalent receptor, 2•Q82, bound to one equivalent 
of divalent peptides, 5, and the trivalent receptor, 3•Q83, bound to one equivalent of trivalent peptide, 
6.16  The presence of all complexes was confirmed by ESI-MS. 
Average Ka values were consistently 2 x 10
4 M-1 for complexation with monovalent peptides, 4.  
The increase in binding affinity due to multivalency was an average 31-fold for divalent complexes, 
2•Q82•5, and 280-fold for the trivalent complex, 3•Q83•6.  In all cases, binding was exothermic (∆H < 
0), enthalpically driven (|∆H| > |T∆S|), and entropically unfavorable (–T∆S > 0).  The magnitude of 
enthalpy and entropy increased with the valency of the target peptide.  Divalent complexes had 
approximately twice the enthalpy of the monovalent complexes (average ∆∆H = -11.7 kcal/mol), but 
more than twice the entropy (average -T∆∆S = 9.7 kcal/mol), resulting in the 31-fold increase in 
affinity.  The trivalent complex had approximately three times the enthalpy of the monovalent 
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complexes (∆∆H = -26.9 kcal/mol), but substantially more than three times the entropy (-T∆∆S = 23.5 
kcal/mol), resulting in the 280-fold increase in affinity.   
 
Table 2.  Thermodynamic Data for Binding of Assembled Receptors to Target Peptides. 
Receptor Target na 
Ka
b 
(M-1) 
Gc 
(kcal/mol) 
Hb 
(kcal/mol) 
-TSd 
(kcal/mol) 
1a•Q8 
1a•Q8 
1b•Q8 
1b•Q8 
4a 
4b 
4a 
4b 
1.02 
1.06 
1.03 
1.03 
2.2 (±0.1) x 104 
2.2 (±0.1) x 104 
1.9 (±0.1) x 104 
2.2 (±0.1) x 104 
-5.9 (±0.1) 
-6.0 (±0.1) 
-5.9 (±0.1) 
-6.0 (±0.1) 
-10.8 (±0.1) 
-11.0 (±0.1) 
-10.8 (±0.2) 
-11.0 (±0.1) 
  4.9 (±0.1) 
  5.0 (±0.1) 
  4.9 (±0.2) 
  4.9 (±0.1) 
2a•Q82 
2a•Q82 
2b•Q82 
2b•Q82 
4a 
4b 
4a 
4b 
2.07 
2.07 
1.95 
1.94 
1.7 (±0.1) x 104 
1.5 (±0.1) x 104 
1.8 (±0.2) x 104 
1.4 (±0.1) x 104 
-5.8 (±0.1) 
-5.8 (±0.1) 
-5.8 (±0.1) 
-5.7 (±0.1) 
-12.8 (±0.2) 
-13.0 (±0.3) 
-11.8 (±0.1) 
-12.3 (±0.1) 
  7.0 (±0.2) 
  7.2 (±0.4) 
  5.9 (±0.1) 
  6.6 (±0.1) 
2a•Q82 
2a•Q82 
2b•Q82 
2b•Q82 
5a 
5b 
5a 
5b 
1.05 
1.07 
1.04 
1.01 
5.0 (±0.1) x 105 
4.6 (±0.1) x 105 
5.5 (±0.1) x 105 
5.0 (±0.1) x 105 
-7.8 (±0.1) 
-7.8 (±0.1) 
-7.9 (±0.1) 
-7.8 (±0.1) 
-24.2 (±0.1) 
-24.8 (±0.4) 
-23.4 (±0.1) 
-24.3 (±0.2) 
16.3 (±0.1) 
17.1 (±0.4) 
15.6 (±0.1) 
16.5 (±0.2) 
3•Q83 
3•Q83 
4a 
6 
2.97 
1.01 
1.7 (±0.1) x 104 
4.7 (±0.8) x 106 e 
-5.8 (±0.1) 
-9.2 (±0.1) e 
-12.2 (±0.1) 
-39.4 (±1.4) e 
  6.4 (±0.2) 
30.2 (±1.5) e 
a Observed molar ratio of target:receptor.  Standard deviations are less than 4%.  b Mean values 
measured from at least three ITC experiments at 27 C in 10 mM sodium phosphate, pH 7.0.  Standard 
deviations are given in parentheses.  c Gibbs free energy values calculated from Ka values.  Standard 
deviations for G values were calculated as the relative error observed in Ka, due to their relationship by 
a natural logarithm.  d Entropic contributions to G calculated from Ka and H values, with error 
propagated from that of Ka and H.  e Data for the 3•Q83•6 complex were determined as described in 
footnote 16. 
 
UV-Visible Spectroscopy.  Figure 4 shows an overlay of UV-visible spectra for complexes 
1a•Q8•4a, 2a•Q82•5a, and 3•Q83•6, plotted as molar absorptivities.17  The average charge-transfer 
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absorptivity at 480 nm (480) for all 2•Q82•5 complexes (795 ± 9 M-1cm-1) was twice that for all 1•Q8•4 
complexes (391 ± 8 M-1cm-1), and the 480 for 3•Q83•6 (1193 M-1cm-1) was three times the average 480 
for all 1•Q8•4 complexes. 
 
 
Figure 4.  UV-visible spectra of representative monovalent (1a•Q8•4a), divalent (2a•Q82•5a), and trivalent complexes (3•Q83•6), plotted in 
molar absorptivity. 
 
Discussion 
Design Considerations.  Compounds 1-6 (Figure 3) have the principle advantage of being easy to 
synthesize and modify.  In designing this series, we addressed several important issues:  1) The linkage 
between binding sites can participate in binding and must therefore be controlled if one wants to obtain 
a meaningful comparison between monovalent and higher valency complexes.  We addressed this issue 
by designing the compounds in a truly modular fashion, where divalent and trivalent compounds are 
two-fold and three-fold repeats of their monovalent analogues, including the peptide backbone.  2) To 
help ensure that multiple binding sites on a single compound can interact simultaneously with their 
targets, we designed the linkage between binding sites to be conformationally flexible and of sufficient 
length to accommodate multiple Q8 molecules.  A logical starting point was to make the Trp-containing 
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target peptides, 4-6,14 sequentially analogous to the viologen-containing scaffold compounds, 1-3, using 
flexible Gly residues for the linkage.  We found that an exact trivalent analogue of 4a has a solubility 
limit of ~1 M, which precludes analysis by ITC (while keeping viologen•Q8 complexes saturated).  An 
analogue with two additional Asp residues at each terminus was prepared.  The resulting compound 6 is 
soluble in excess of 200 M.  Prior work on the binding of Q8•MV to tryptophan derivatives and Trp-
containing peptides suggests that the negative charges will have negligible effect on binding.  3) All 
structures must be designed to minimize unintended adhesion of Q8 to sufficiently hydrophobic and/or 
electropositive sites.  We addressed this concern by placing positive charges on only the viologen 
groups and by keeping alkyl chains to a length of three or fewer carbons.18  N-termini were acetylated, 
and C-termini were primary amides in order to reduce the effects of electrostatic charge at these 
positions.11  
 
Self-Assembly of Receptors.  All scaffolds, 1-3, bound to Q8 with Ka values of 2 x 10
6 M-1 per 
binding site.15  The similarity of these binding constants to each other and to those observed previously 
for the binding of Q8 to methyl viologen (Ka = 8.5 x 10
5 M-1) supports a similar mode of binding among 
these complexes, demonstrates that linking viologen groups to these scaffolds does not diminish their 
ability to bind to Q8, and exemplifies the non-cooperativity of this process.  The small increase in the 
binding affinity to Q8 for scaffolds 1-3 relative to methyl viologen may be due to additional dipole-
dipole interactions between Q8 and the amide NH groups on the linker and/or scaffold, as observed in 
previous structural studies of Q8•peptide complexes.19  The ability of scaffolds 2 and 3 to bind two and 
three equivalents of Q8, respectively, with no change in binding affinity shows that the multivalent 
scaffolds are able to accommodate the steric demands of multiple Q8 molecules without an energetic 
penalty. 
 
Monovalent Peptide Targets.  Receptor complexes, 1•Q8, 2•Q82, and 3•Q83, bound to monovalent 
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target peptides, 4, with Ka values of approximately 2 x 10
4 M-1 per binding site.15  The consistency 
among these values and that observed previously for Q8•MV binding to Gly-Gly-Trp-Gly-Gly (Ka = 2.5 
x 104 M-1)11 supports a similar mode of binding among these complexes, shows that linkage of 
viologen•Q8 complexes to these scaffolds does not adversely affect their ability to bind to Trp-
containing peptides, and exemplifies the noncooperativity of this process.  Moreover, the binding of 
multivalent receptor complexes, 2•Q82 and 3•Q83, to two and three equivalents, respectively, of 
monovalent peptide shows that the multivalent receptors are able to simultaneously accommodate the 
steric demands of multiple monovalent target molecules with no energetic penalty.  The consistency and 
predictability observed for the binding of Q8 and, subsequently, of monovalent peptide establishes an 
essential baseline for their comparison to multivalent analogues. 
 
Divalent Peptide Targets:  Mode of Binding.  In studying the binding of divalent receptors, 2•Q82, 
to their analogous multivalent target peptides, 5, we first needed to provide evidence for the mode of 
binding.  Specifically, we were concerned about the formation of supramolecular oligomers instead of, 
or in addition to, the desired discrete multivalent complexes (Figure 5).  To assign the mode of binding, 
we present the following case. 
Our system has the characteristic that simultaneous inclusion of viologen and indole groups in the 
cavity of Q8 produces a quantitative increase in visible absorbance, which is due to the formation of a 
charge-transfer complex between the two aromatic groups.11, 12b  Therefore, the molar absorptivity due 
to this charge-transfer complex is related directly to the number of simultaneous binding events per 
molecule.  The UV-visible spectral data (Figure 4) show that the charge-transfer absorptivities of the 
divalent and trivalent complexes are two-fold and three-fold greater, respectively, than those of the 
monovalent complexes.  This result shows that >95% of the possible Q8•viologen•tryptophan 
complexes are simultaneously formed, and would be true only for discrete multivalent complexes as 
well as for long (>20-mer) supramolecular oligomers. 
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Figure 5.  Schematic illustration of the stepwise binding of a divalent receptor with a divalent target peptide.  In the first step, intermolecular 
association (Kinter) yields a complex which can either close intramolecularly (Kintra) into a discrete complex or associate intermolecularly with 
additional divalent compounds (Kinter
n) into a supramolecular oligomer. 
ITC data for the formation of divalent (2•Q82•5) complexes show a single-phase isotherm (Figure 
6), which fits well to a one-set-of-sites binding model and which has an inflection point at a 1:1 molar 
ratio of target:receptor.  Considering the argument presented in the following paragraph, this result 
suggests that only one type of binding mode is occurring throughout the titration:  1) each molecule of 
target peptide binds once to a receptor molecule; or 2) each molecule of target binds multiple times to a 
receptor molecule.  The UV-visible spectra discussed in the previous paragraph effectively rule out 
option 1.  Moreover, the observed binding enthalpies for the formation of 2•Q82•5 complexes are 
approximately two-fold greater than those for the formation of 1•Q8•4, as expected for the binding of 
two identical sites connected by a flexible linker.1a  The combination of these results and the fact that 
oligomeric species were not observed by mass spectrometry leads us to conclude that these complexes 
form in a discrete, multivalent fashion. 
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Figure 6.  ITC data for the binding of divalent target peptide 5a to divalent receptor assembly 2a•Q82 at 27 °C in 10 mM sodium phosphate 
buffer, pH 7.0.  5a was titrated at 0.60 mM into a 0.065 mM sample of 2a•Q82.  The top plot shows the raw data for power applied as a 
function of time.  The integrated enthalpy values are plotted at the bottom as a function of the molar ratio of 5a:2a•Q82. 
Supramolecular oligomerization can be ruled out on the basis of the ITC data by considering the 
following argument.  Early in the titration of a divalent target peptide into a solution of divalent 
receptor, there is a vast excess of available receptor.  If oligomerization were favored, then each 
molecule of target would bind to two equivalents of receptor such that both tryptophan residues were 
occupied.  The Caruthers equation (Eq. 1) predicts the number average degree of polymerization, Xn, on  
Xn, = 1/(1-p)      Eq. 1 
the basis of extent of reaction, p.  We determined p values from the equilibrium constants reported in 
Table 2 and the experimental concentrations.  This equation predicts an average length of two units at a 
target:receptor ratio of 1:2, three units at a ratio of 3:4, and six units at the equivalence point.  Over this 
portion of the titration, newly titrated target molecules could bind to two free receptors or could link a 
free receptor to a growing oligomer; in both cases, the measured enthalpy would reflect the binding of 
both Trp residues per molecule of titrant.  Near and after the equivalence point, however, the probability 
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of newly titrated target molecules to bind to multiple free receptor sites becomes very low.  Therefore, 
the titration experiment should show at least two phases:  1) before the equivalence point, a phase which 
reflects the enthalpy of binding for two Trp residues per titrated target molecule; and 2) after the 
equivalence point, a phase which reflects the enthalpy of binding of one Trp residue per titrated target 
molecule.  Our observation of a single-phase isotherm is inconsistent with this model, and thus we rule 
out the formation of oligomers. 
 
Divalent Peptide Targets: Effects of the Distance Between Binding Sites.  In order to assess 
whether the distance between binding sites influences the formation of divalent complexes, we varied 
the oligo(Gly) linker between viologen groups in divalent scaffolds, 2, and between tryptophan residues 
in divalent targets, 5, between four (2a and 5a) and six (2b and 5b) Gly units.  As seen from the data in 
Table 2, no significant difference was observed.  Similarly there was no significant difference observed 
for the analogous monovalent derivatives, 1a, 1b, 4a, and 4b.  These results are not surprising given the 
expectation that oligo(Gly) linkers would have little conformational preference. 
The similarities observed here allow us to simplify subsequent analysis of the thermodynamic data 
by averaging the values all four combinations of scaffold and target for each type of complex (Table 3).  
For example, data for the formation of 1a•Q8•4a, 1b•Q8•4a, 1b•Q8•4a, and 1b•Q8•4b is shown simply 
as 1•Q8•4, with an uncertainty determined by propagating the error in each experiment through the 
calculation of an average. 
 
 
Table 3.  Average thermodynamic constants for Gly4 vs. Gly6 linkers.
a 
Receptor 
Ka 
(M-1) 
G 
(kcal/mol) 
H 
(kcal/mol) 
-TS 
(kcal/mol) 
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1•Q8•4 
2•Q82•42 
2•Q82•5 
2.1 (±0.1) x 104 
1.6 (±0.1) x 104 
5.0 (±0.2) x 105 
-6.0 (±0.1) 
-5.8 (±0.1) 
-7.8 (±0.1) 
-10.9 (±0.1) 
-12.5 (±0.3) 
-24.2 (±0.3) 
  4.9 (±0.1) 
  6.7 (±0.3) 
16.4 (±0.4) 
a All values are averages of the constants reported in Table 2 for all four combinations of Gly4 and 
Gly6 linkages.  Errors were calculated by propagating the uncertainties reported in Table 2 through the 
calculation of an average. 
 
Divalent Peptide Targets: Thermodynamic Considerations.  Table 3 allows us to conveniently 
compare binding data for monovalent and divalent complexes.  We observe an increase in Ka of 31-fold 
due to the second binding event.  This increase is a significant improvement over monovalent binding, 
but an ideal system could theoretically yield an increase on the order of 104-fold.1a The observed trend 
in Ka values results from an approximate doubling of the binding enthalpies but at a substantial cost in 
entropy.  The additive enthalpy suggests that (i) both Trp residues are able to simultaneously associate 
with their binding sites without steric penalty, and (ii) entropy is entirely to blame for the negative 
cooperativity observed here. 
In order to properly analyze the effects of divalent versus monovalent binding, we include a 
treatment of symmetry factors, as outlined by Ercolani,3f and dissect this process into the constituent 
inter- and intramolecular binding events.   In the formation of the 2+2 complex, 2•Q82•5, binding of the 
first Trp residue is designated as Kinter, and binding of the second as Kintra (Figure 5).  A Kinter value of 
5.5 x 103 M–1 is derived from the observed equilibrium constant (Kobs(1+1), Eq. 2)
20 for the formation of 
the  
Kobs(1+1) = 4 Kinter      Eq. 2 
monovalent complex, 1•Q8•4.  The observed equilibrium constant for the formation of 2•Q82•5, Kobs(2+2) 
(Eq. 3), is expressed in terms of Kinter  and Kintra, where  = 2 for the overall reaction.  This analysis 
Kobs(2+2) = 2 Kinter Kintra     Eq. 3 
yields a Kintra value of 45.  Prior work
4b, 21 has shown that flexible divalent compounds have an effective 
molarity (EM) of approximately 5 mM, referring to the ratio of Kintra /2 Kinter (where  = 1/2).  If our 
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Kinter = 5.5 x 10
3 M-1, then an EM of 5 mM would predict a Kintra value of 55.  The similarity of this 
prediction to the actual value reported here (45) provides another example of the regular behavior of this 
system and thus its suitability as a model for multivalent interactions. 
The detailed thermodynamic data provide an opportunity to dissect the formation divalent 
complexes by isolating the effects of linking two monovalent receptors (1•Q8 vs. 2•Q82) or two 
monovalent target peptides (4 vs. 5).  The most direct comparison of thermodynamic data in these three 
complexes would require normalization to the same number of Q8•viologen•Trp interactions per 
complex.  The modular design used in this system allows us to accomplish this estimation by doubling 
the values of G, H, and -TS for the formation of 1•Q8•4 and 2•Q82•42 because these are average 
values for each Q8•viologen•Trp interaction.22 From this comparison (Table 4), one can deduce that 
linking two monovalent receptors (i.e., 2•Q82•42 vs. 1•Q8•4) results in a 3.2 kcal/mol increase in 
exothermicity with an almost exact 3.6 kcal/mol compensation in entropic energy.  Linking two 
monovalent target peptides (i.e., 2•Q82•5 vs. 2•Q82•42) results in a 3.0 kcal/mol entropic penalty with a 
relatively small 0.8 kcal/mol loss in enthalpy.  On the basis of this analysis, the suboptimal binding 
affinity observed in the formation of the 2•Q82•5 complex derives primarily from an entropic penalty 
associated with the binding of divalent versus monovalent peptide.  This analysis is consistent with a 
model in which significant conformational freedom is lost upon formation of the divalent complex.  
 
 
 
 
 
Table 4.  Dissection of the influence of linkage on divalent binding.a 
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Complex multiplier 
G 
(kcal/mol) 
H 
(kcal/mol) 
-TS 
(kcal/mol) 
1•Q8•4 
2•Q82•42 
2•Q82•5 
2 
2 
1 
-12.0 
-11.6 
  -7.8 
   -21.8 
   -25.0 
   -24.2 
     9.8 
   13.4 
   16.4 
a These are values from Table 3 multiplied by the “multiplier” in the second column so that all values 
represent the binding of two Trp residues per complex. 
 
Divalent Peptide Targets: A Model for Multivalent Binding.  It is useful to compare our divalent 
system to an antibody molecule (e.g., IgG), in which the binding of the second site confers a modest 
100-fold increase in affinity.23 The wide range of conformations observed for IgG molecules suggests a 
substantial conformational flexibility in the “hinge” that connects the two binding sites.24 The functional 
role of this flexibility remains a topic of current research, but the enormous size and structural 
complexity of antibody molecules substantially complicates these efforts.  This example underscores the 
challenges involved in carrying out detailed studies of multivalent processes on proteins.  As in many 
other successful areas of science, a good model system—one that embodies the essential characteristics 
of multivalency but is especially easy to study—is needed. 
In addition to its importance as a submicromolar receptor for peptides in aqueous solution, the 
divalent system presented here has numerous features that make it well suited to serve as a model for 
studying multivalent complexation:  1) The monovalent complex is well understood.  2) The mode of 
divalent binding is simple, well defined, and similar to that observed for covalently linked multivalent 
receptors.  That is, assembly of the divalent complexes proceeds noncooperatively, divalent complexes 
form in a discrete (non-oligomeric) fashion, and the observed intramolecular binding constant, Kintra, is 
similar to that of other flexible divalent complexes.  3) Synthesis is straightforward.  Solid-phase 
synthetic methodology combined with noncovalent self-assembly enables the efficient synthesis of 
receptors and iterative modification of their linkers.  4) Analysis is straightforward.  ITC combined with 
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UV-visible spectroscopy allows for rapid determination of binding mode and quantitative measurement 
of the valency of the complex.  Optical sensing of peptide targets is an additional benefit.  5) The system 
has several features that are representative of multivalent complexes in biological systems.  The 
complexes form in neutral, buffered aqueous solution, the target compounds are peptides, and there is an 
observable increase in affinity due to multivalency.  6) The weaker than optimal increase in affinity is 
representative of antibodies and is desirable because it provides ample opportunity to uncover design 
principles for increasing the binding affinity through structure-activity studies. 
 
Trivalent Peptide Target.  Given the well-defined and predictable nature of the divalent complexes 
described above, we asked what would happen if the valency were extended to three.  Based on the lack 
of distance-dependence observed in the divalent system, scaffold compound 3 and target peptide 6 were 
designed with only four intervening Gly residues between binding sites. The charge-transfer 
absorptivity of the trivalent complex, 3•Q83•6, is three times that observed for the monovalent 
complexes, 1•Q8•4 (Figure 4). As discussed in detail for the divalent system above, this result 
demonstrates that essentially all of the available tryptophan residues are bound simultaneously, but it 
does not in itself allow for the unambiguous determination of binding mode.  In the divalent complex, 
the two binding sites per molecule allow for only two possible binding modes:  discrete macocycles and 
daisy-chain-like oligomers.  In the trivalent system, the three binding sites per molecule enable more 
possible configurations, but the observed condition that all sites are bound simultaneously suggests that 
the only probable binding modes are discrete complexes and linear oligomers. 
 The ITC data for the trivalent complex shows a single transition centered at a 1:1 (6 : 3•Q83) 
ratio (see Supporting Information, Figure S21).  In contrast to the divalent system, however, the 
isotherm for the trivalent complex shows some asymmetry, with a steeper decrease in the magnitude of 
enthalpy in the first 2/3 of the injections.16  This region fits well to a one-set-of-sites model, but the 
more shallow curvature of the remaining 1/3 of the data points suggests an additional binding mode, the 
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nature of which is unclear at this time.  This result is not dramatic, but it is real, and it precludes the 
definitive assignment of this complex as discrete versus oligomeric.  Given that (i) there is a clear 
midpoint at a 1:1 ratio, (ii) the first ~2/3 of the data points, including the early baseline and most of the 
transition region, is well defined by the data, and (iii) the end of the titration is defined by the heat of 
dilution, we estimated thermodynamic constants by fitting the first 2/3 of the titration data to a one-set-
of-sites model.  It should be noted that the UV-visible spectroscopy data in Figure 4 were acquired at 
the equivalence point, and thus are within the region defined by this analysis.  Mass spectral data also 
verify the presence of the 3•Q83•6 complex.   
Although the binding mode is not definitive, the data provide a look at the properties of what is 
likely a discrete trivalent complex.  With these qualifications in mind, we observe an increase in Ka of 
~280-fold due to multivalency, which is an enhancement of ~10-fold for the addition of a third binding 
site.  This increase results from an approximate tripling of the favorable binding enthalpy and a more 
than tripling of the unfavorable binding entropy.  The additive enthalpy is very similar to that observed 
for the divalent complexes; this similarity supports an assignment of a discrete trivalent complex. 
As described above for the divalent complex, the observed binding constant for the formation of 
3•Q83•6, Kobs(3+3), can be evaluated on the basis of the constituent inter- and intramolecular binding 
constants, Kinter and Kintra.  Using the approach detailed above for the divalent complexes,
3f we derive a 
Kinter value of 1.1 x 10
4 M–1 and a Kintra value of 15.  The Kintra value is therefore approximately 3-fold 
smaller than that of the divalent complex.  Based on the argument that only K values of the same 
dimensionality can be directly compared to assess cooperativity,3f we conclude that the trivalent system 
shows a small degree of negative cooperativity as compared to the divalent complex. 
Also as described for the divalent complex, the thermodynamic data for 3•Q83•6 can be dissected to 
assess the relative effects of linking three monovalent scaffolds (i.e., 1•Q8•4 vs. 3•Q83•43) or three 
monovalent targets (i.e., 3•Q83•43 vs. 3•Q83•6).  In order to normalize to the same number of binding 
events per complex, however, the thermodynamic state functions for 1•Q8•4 and 3•Q83•43 must be 
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multiplied by a factor of 3.  The resulting values (Table 5) show that linkage of three monovalent 
scaffolds leads to a 3.9 kcal/mol increase in favorable enthalpy with a compensating 4.5 kcal/mol 
increase in unfavorable entropy.  Linkage of three monovalent target peptides provides an additional 2.8 
kcal/mol in favorable enthalpy but with a massive 11 kcal/mol loss in entropic energy.  This trend is 
very similar to that observed for the divalent complex (as in Table 5); this similarity further supports an 
assignment of a discrete trivalent complex.  The increasing loss in entropy in this system versus the 
divalent complexes is likely due to a decreasing probability of adopting a conformation in which all 
three sites are simultaneously bound without enthalpic penalty due to steric strain.  If this trend is 
linearly extrapolated to complexes of higher valency, we would predict that starting with a heptavalent 
complex, the influence of multivalency would actually reduce the overall binding affinity. 
Multivalent binding is often thought to be an entropically favorable process due to the reduced 
entropic penalty of translational and rotational freedom upon binding of two n-valent compounds as 
compared to the binding of n pairs monovalent analogues.1a The contribution of this entropic advantage 
to the free energy of binding has been approximated at ~5 kcal/mol per increase in the reaction 
order.3a,25  Using this approximation, the entropic contribution to the free energy of binding of a divalent 
complex should be twice that of a monovalent complex less 5 kcal/mol; we observe an additional 8-12 
kcal/mol entropic penalty beyond this approximation.  Similarly, the entropic contribution to the free 
energy of binding of a trivalent complex should be three times that of a monovalent complex less 10 
kcal/mol; we observe an additional 21-26 kcal/mol entropic penalty beyond this approximation.  These 
results are in stark contrast to the expected entropic advantage of multivalency.  The nature of this effect 
remains unclear. 
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Table 5.  Dissection of the influence of linkage on trivalent binding.a 
Complex multiplier 
G 
(kcal/mol) 
H 
(kcal/mol) 
-TS 
(kcal/mol) 
1•Q8•4 
3•Q83•43 
3•Q83•6 
3 
3 
1 
-18.0 
-17.4 
  -9.2 
   -32.7 
   -36.6 
   -39.4 
   14.7 
   19.2 
   30.2 
a These are values from Tables 2 (1•Q8•4) and 3 (3•Q83•43 and 3•Q83•6) multiplied by the 
“multiplier” in the second column so that all values represent the binding of three Trp residues per 
complex. 
 
Conclusion 
This paper demonstrates a novel biomimetic approach to the construction of well-defined 
multivalent receptors via molecular self-assembly.  We present a new class of synthetic receptors that 
assemble spontaneously from a modular scaffold presenting 1-3 viologen groups and an equivalent 
number of Q8 molecules.  This noncovalent synthetic approach provides unparalleled economy for the 
purpose of iterative design and synthesis of multivalent receptors.  We show that preassembled 
receptors bind to peptides containing multiple Trp residues in a multivalent fashion with affinity gains 
of 31-280-fold due to multivalency.  The built-in optical sensor for tryptophan enables rapid and direct 
determination of the extent of valency using UV-visible spectroscopy, thus overcoming a common 
pitfall in the analysis of multivalent complexes.  This technique, in combination with calorimetry and 
careful modular design of the scaffolds and targets, allows for convenient determination of the binding 
mode and comprehensive analysis of the binding thermodynamics.  In addition to these advantages in 
synthesis and analysis, this system has several characteristics that make it remarkably well suited as a 
model for multivalent complexes:  1) It works in water.  2) The monovalent complex is well 
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characterized. 3) Receptor assembly is noncooperative, and binding is additive; these features hugely 
simplify the equilibrium analysis.  This system should facilitate iterative studies of structure-activity 
relationships in multivalent complexes, such as the effects of conformational entropy, ligand geometry, 
and higher valency.  These studies are currently underway and will be reported in due course. 
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